STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish biotech company Karo Bio (Reuters: KARO.ST) (STO:KARO) today announced that it has expanded and further strengthened the intellectual property portfolio for its thyroid hormone receptor (TR) platform by entering into an agreement that provides Karo Bio with an exclusive license to a US patent from Pfizer Inc.
